Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 4:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 58 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Ischemic Reperfusion Injury Clear all
Completed Phase 1Phase 2 Interventional Results available

Berinert (C1INH) vs Placebo for DGF/IRI

NCT04696146
View directory record Official record
Conditions
End Stage Renal Disease, Chronic Kidney Diseases
Interventions
Berinert, Placebo
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 3, 2024 · Synced Jul 21, 2026, 4:53 AM EDT
Not yet recruiting Phase 3 Interventional

Xenon for Neuroprotection During Post-Cardiac Arrest Syndrome in Comatose Survivors of an Out of Hospital Cardiac Arrest

NCT03176186
View directory record Official record
Conditions
Post-Cardiac Arrest Syndrome
Interventions
Xenon
Combination Product
Lead sponsor
Invero Pharma, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,436 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
8
States / cities
Hartford, Connecticut • Gainesville, Florida • Gulfport, Mississippi + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2025 · Synced Jul 21, 2026, 4:53 AM EDT
Completed Not applicable Interventional

N-acetylcysteine in Liver Transplantation

NCT00736541
View directory record Official record
Conditions
End Stage Liver Failure
Interventions
N-acetylcysteine
Drug
Lead sponsor
Ibtesam Hilmi
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 27, 2023 · Synced Jul 21, 2026, 4:53 AM EDT
Not yet recruiting Early Phase 1 Interventional Accepts healthy volunteers

Therapeutic Strategies to Reduce Endothelial Ischemia-reperfusion Injury

NCT06825143
View directory record Official record
Conditions
Metabolic Syndrome, Vascular Injury, Ischemic Preconditioning, Endothelial Function (reactive Hyperemia), Endothelial Dysfunction
Interventions
Ischemic preconditioning, Intravenous lactate infusion, No ischemic preconditioning (control), Normal Saline Infusion (Placebo), Ischemic preconditioning and intravenous lactate
Procedure · Drug · Combination Product
Lead sponsor
Gary Van Guilder
Other
Eligibility
18 Years to 65 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Gunnison, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 12, 2025 · Synced Jul 21, 2026, 4:53 AM EDT
Suspended Phase 1 Interventional

Minimizing Reperfusion Injury in Patients With Acute Myocardial Infarction

NCT00846378
View directory record Official record
Conditions
Acute Myocardial Infarction
Interventions
Post conditioning, Usual Care for STEMI
Procedure
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 2, 2014 · Synced Jul 21, 2026, 4:53 AM EDT
Not listed Phase 2 Interventional

YSPSL for Prevention of Ischemic Reperfusion Injury in Patients Undergoing Cadaveric Orthotopic Liver Transplantation

NCT00876902
View directory record Official record
Conditions
Ischemia Reperfusion Injury
Interventions
recombinant P-selectin glycoprotein ligand Ig fusion protein, Viaspan® and saline
Drug
Lead sponsor
Y's Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 6, 2009 · Synced Jul 21, 2026, 4:53 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Intermittent Hypoxia on Ischemia-reperfusion Injury in Healthy Individuals

NCT05423470
View directory record Official record
Conditions
Intermittent Hypoxia
Interventions
Intermittent hypoxia, Intermittent normoxia
Behavioral
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years to 80 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Dec 6, 2022 · Synced Jul 21, 2026, 4:53 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Anesthetics to Prevent Lung Injury in Cardiac Surgery

NCT02918877
View directory record Official record
Conditions
Inflammatory Lung Injury, Ischemia-Reperfusion Lung Injury, Postoperative Pulmonary Complications
Interventions
Sevoflurane, Propofol
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 4, 2021 · Synced Jul 21, 2026, 4:53 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Intravenous Estrogen in Kidney Transplant Study

NCT03663543
View directory record Official record
Conditions
Ischemia Reperfusion Injury
Interventions
Conjugated Estrogen, Normal saline
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
21 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Jul 21, 2026, 4:53 AM EDT
Completed Phase 3 Interventional

A Safety and Efficacy Study to Confirm the Cardioprotective Effects of MC-1 in Patients Undergoing High-Risk CABG

NCT00402506
View directory record Official record
Conditions
Coronary Artery Bypass Graft Surgery, Myocardial Ischemia, Reperfusion Injury
Interventions
(MC-1) Pyridoxal 5'-phosphate
Drug
Lead sponsor
Medicure
Industry
Eligibility
18 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 15, 2007 · Synced Jul 21, 2026, 4:53 AM EDT
Completed No phase listed Observational

Novel Imaging Biomarkers for Mechanical Complications in Acute Myocardial Infarction

NCT06450912
View directory record Official record
Conditions
Acute Myocardial Infarction, Hemorrhagic Myocardial Infarction, Myocardial Stunning, Myocardial Hemorrhage, Myocardial Reperfusion Injury, Myocardial Rupture (Post Infarct)
Interventions
Not listed
Lead sponsor
Rohan Dharmakumar
Other
Eligibility
18 Years to 79 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Jul 21, 2026, 4:53 AM EDT
Completed No phase listed Observational

Intestinal Ischemia as a Stimulus for Systemic Inflammatory Response After Cardiac Arrest

NCT01944605
View directory record Official record
Conditions
Cardiac Arrest, Reperfusion Injury
Interventions
Not listed
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 5, 2017 · Synced Jul 21, 2026, 4:53 AM EDT
Completed Phase 2 Interventional Results available

Sodium Nitrite in Acute Myocardial Infarction

NCT00924118
View directory record Official record
Conditions
Acute Myocardial Infarction
Interventions
Sodium Nitrite
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
3
States / cities
Baltimore, Maryland • Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 13, 2018 · Synced Jul 21, 2026, 4:53 AM EDT
Terminated Phase 1 Interventional

Use of the Cardioprotectant Dexrazoxane During Congenital Heart Surgery: Proposal for Pilot Investigation

NCT02519335
View directory record Official record
Conditions
Heart Defects, Congenital
Interventions
Dexrazoxane
Drug
Lead sponsor
Medical City Children's Hospital
Other
Eligibility
1 Day to 6 Months
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 25, 2018 · Synced Jul 21, 2026, 4:53 AM EDT
Completed Not applicable Interventional

Post-conditioning to Reduce Infarct Size

NCT00755469
View directory record Official record
Conditions
Myocardial Infarction
Interventions
Post-conditioning
Procedure
Lead sponsor
Minneapolis Heart Institute Foundation
Other
Eligibility
18 Years to 80 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 4, 2013 · Synced Jul 21, 2026, 4:53 AM EDT
Not listed Phase 2 Interventional

YSPSL for Prevention of Delayed Graft Function in Cadaveric Liver Transplantation

NCT00450398
View directory record Official record
Conditions
Liver Diseases
Interventions
YSPSL, Placebo
Drug
Lead sponsor
Y's Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 28, 2008 · Synced Jul 21, 2026, 4:53 AM EDT
Terminated Phase 2Phase 3 Interventional

A Study to Evaluate the Effect of ASP8597 in Adult Kidney Transplant Patients

NCT01442337
View directory record Official record
Conditions
Kidney Transplantation
Interventions
ASP8597, Placebo
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years to 70 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
19
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2014 · Synced Jul 21, 2026, 4:53 AM EDT
Completed Phase 1 Interventional

The Safety of Vardenafil in Patients Undergoing Cardiac Surgery

NCT01260285
View directory record Official record
Conditions
Ischemia-reperfusion Injury.
Interventions
Vardenafil
Drug
Lead sponsor
McGuire Research Institute
Other
Eligibility
18 Years to 90 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 3, 2011 · Synced Jul 21, 2026, 4:53 AM EDT
Completed Phase 2 Interventional

Phase 2 Study of the Safety of Diannexin in Kidney Transplant Recipients

NCT00615966
View directory record Official record
Conditions
Kidney Transplantation
Interventions
Diannexin, Placebo
Drug
Lead sponsor
Alavita Pharmaceuticals Inc
Industry
Eligibility
21 Years to 70 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
5
States / cities
Baltimore, Maryland • Livingston, New Jersey • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2011 · Synced Jul 21, 2026, 4:53 AM EDT
Terminated Phase 2 Interventional Results available

Nitrite Infusion in Islet Cell Transplantation

NCT03544242
View directory record Official record
Conditions
Diabetes
Interventions
Control, Pre-Isolation Infusion, Post-Isolation Infusion
Other · Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 28, 2020 · Synced Jul 21, 2026, 4:53 AM EDT
Completed No phase listed Observational

Reoxygenation After Cardiac Arrest (REOX Study)

NCT01881243
View directory record Official record
Conditions
Cardiac Arrest
Interventions
Not listed
Lead sponsor
The Cooper Health System
Other
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
5
States / cities
Indianapolis, Indiana • Boston, Massachusetts • Jackson, Mississippi + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2019 · Synced Jul 21, 2026, 4:53 AM EDT
Recruiting Phase 1Phase 2 Interventional

Safety and Efficacy of Treprostinil (Remodulin®) In Reducing Ischemia-Reperfusion Injury During Kidney Transplantation

NCT04005469
View directory record Official record
Conditions
Ischemia Reperfusion Injury, Delayed Graft Function
Interventions
Treprostinil
Drug
Lead sponsor
Rhode Island Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Jul 21, 2026, 4:53 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of Myocardial Effects of MTP-131 for Reducing Reperfusion Injury in Patients With Acute Coronary Events

NCT01572909
View directory record Official record
Conditions
Reperfusion Injury, STEMI
Interventions
Bendavia (MTP-131), Placebo
Drug
Lead sponsor
Stealth BioTherapeutics Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
3
States / cities
Port Orange, Florida • Detroit, Michigan • Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Jun 10, 2020 · Synced Jul 21, 2026, 4:53 AM EDT
Completed Phase 1 Interventional Results available

Reperfusion With Cooling in Cerebral Acute Ischemia

NCT01585597
View directory record Official record
Conditions
Stroke, Acute
Interventions
Zoll- Coolgaurd 3000
Device
Lead sponsor
Emory University
Other
Eligibility
18 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 31, 2014 · Synced Jul 21, 2026, 4:53 AM EDT